To review contemporary management of malignant ovarian germ cell tumors (MOGCT).
INTRODUCTION
One of the greatest success stories within the discipline of gynecologic oncology has been that of malignant ovarian germ cell tumors (MOGCT). What has made this tale so special is the convergence of multiple tumor and host characteristics that combine to lead to optimal outcomes in most patients so affected: rare tumors that principally occur in girls and young women, predominant unilaterality of the adnexal tumor that allows the potential for fertility-sparing surgery, relatively low frequency of advanced-stage disease, excellent chemosensitivity to contemporary platinum-based chemotherapy with concomitant excellent cure rates, and small incidence of severe late effects.
In this article, we will summarize the myriad contributions that have unfolded over the past few decades and have resulted in the foundation of principles on which modern management of MOGCT is based.
CLINICAL PRESENTATION AND INITIAL EVALUATION
Several large case series from the 1970s and 1980s provided a detailed description of the clinical presentation associated with MOGCT. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] These tumors occur principally in girls and young women, with a mean age in the teenage years. Presenting signs and symptoms include abdominal pain and a palpable pelvic-abdominal mass in approximately 85% of patients. Approximately 10% of patients will present with acute abdominal pain mimicking appendicitis, usually caused by rupture, hemorrhage, or torsion of the ovarian tumor. Less common signs and symptoms include abdominal distension (35%), fever (10%), and vaginal bleeding (10%). A small proportion of patients exhibit isosexual precocity related to human chorionic gonadotropin (hCG) production by the tumor.
Many of the MOGCT produce serum tumor markers that can serve as an adjunct in initial diagnosis, monitoring during therapy, and post-treatment surveillance. Yolk sac tumor and choriocarcinoma are the prototypes of alpha-fetoprotein (AFP) and hCG production, respectively. Both embryonal carcinoma and polyembryoma may produce hCG and AFP, the former more commonly. A small percentage of dysgerminomas produce low levels of hCG related to the presence of multinucleated syncytiotrophoblastic giant cells, and approximately one third of immature teratomas produce AFP. Of course, mixed germ cell tumors may produce either, both, or none, depending on the type and quantity of elements present. Occasionally, other serum tumor markers, such as lactic dehydrogenase, may be elevated in patients with MOGCT, particularly dysgerminoma.
Initial evaluation of a patient with a suspected MOGCT based on history and physical examination should include routine blood studies, serum tumor markers, chest x-ray, and imaging studies-pelvic sonography and computed tomography (CT) of the abdomen and pelvis. If dysgenetic gonads are suspected based on physical findings and a history of primary amenorrhea, then karyotyping is indicated.
PATHOLOGY
Rare tumors, such as MOGCT, are quite difficult to study. One of the major factors contributing to this situation is the multiplicity of histologic patterns involved and the lack of uniformity in their nomenclature. Thanks to a generation of gynecologic pathologists who focused on these fascinating neoplasms-foremost among whom were Robert E. Scully, H. J. Norris, and Aleksander Talerman-a useful classification system began to take shape in the 1970s and has been repeatedly refined to its current state as the 2003 WHO classification system (Table 1) . [11] [12] [13] Concomitantly, in the early part of this era, several publications detailed the clinicopathologic characteristics of MOGCT. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Practically, it is most helpful to subdivide MOGCT into dysgerminoma-the most common type and the counterpart of the male seminoma-and nondysgerminomatous tumors. The most common types of nondysgerminomatous tumors are yolk sac tumor, immature teratoma, and mixed germ cell tumors, with embryonal carcinoma, nongestational choriocarcinoma, and polyembryoma being much less common.
In the most recent version of the WHO classification system,
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MOGCT are divided into three categories: primitive germ cell tumors, biphasic or triphasic teratoma, and monodermal teratoma and somatic-type tumors associated with dermoid cysts. 14 Among the recent advances in our understanding of the pathology of MOGCT are the enhanced recognition of the multiple variants of yolk sac tumor (typical, polyvesicular vitelline tumor, glandular, hepatoid, soid, parietal, mesenchyme-like, and those with secondary somatic neoplasm) and the CNS tumor (neuroectodermal tumor) group, which can be divided in three distinct categories (differentiated, primitive, and anaplastic) and for which effective therapy appears to differ markedly from the more typical MOGCT. 14 In fact, the standard chemotherapy regimen for selected patients with primitive germ cell tumors and biphasic or triphasic teratomas does not apply to tumors in the monodermal teratoma and somatictype tumor category. For example, systemic therapy for metastatic tumors within this latter group may include the standard treatment for the primary tumor site (as in the case of a thyroid carcinoma arising in a benign cystic teratoma or a carcinoid tumor) or standard treatment for a tumor type arising from any site (as in the case of a carcinoma, melanoma, or sarcoma arising in a benign cystic teratoma). For the quite rare primitive neuroectodermal tumor, systemic therapy generally consists of multidrug regimens involving such agents as vincristine, cyclophosphamide, doxorubicin, dactinomycin, etoposide, and ifosfamide.
PROGNOSTIC FACTORS
Because of the extreme rarity of MOGCT, identifying prognostic factors has been quite challenging. However, recent studies have confirmed long-standing clinical impressions that the International Federation of Gynecology and Obstetrics staging system's (FIGO) stage, residual disease, histologic type, and elevation of serum tumor markers appear to be prognostic parameters for patients with MOGCT. 15, 16 Lai et al 15 found that advanced FIGO stage and nondysgerminoma/ immature teratoma histology were associated with a significantly increased risk of treatment failure, and nondysgerminoma/immature histology and bulky residual disease after salvage surgery were significantly associated with a worse overall survival. Murugaesu et al 16 reported that, in univariate and multivariate analyses, in addition to FIGO stage, elevation of both hCG and AFP but not when taken alone, was a strong predictor of survival. Neither study found that age at diagnosis was prognostic. 
SURGICAL STRATEGIES

Primary Surgery
Early case series provided details of operative findings in patients with MOGCT, which constitute the foundation on which contemporary surgical principles are based. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] From these studies, we learned that these tumors tend to be quite large, and approximately 60% are confined to the ovary. In addition, the majority are unilateral, with bilateral ovarian involvement occurring in 10% to 15% of pure dysgerminoma, in some mixed germ cell tumors in which the predominant component is dysgerminoma, and in occasional cases of advanced-stage MOGCT in which the disease metastasizes from one ovary to the other. Furthermore, the findings of these studies also demonstrated that benign cystic teratoma is found in 5% to 10% of patients with MOGCT, highlighting the fact that bilateral ovarian involvement does not automatically herald a malignant process.
Fertility-sparing surgery. The above constellation of tumor characteristics presents an optimal opportunity for fertility-sparing surgery in patients with MOGCT. Support for such an approach arises not from prospective randomized trials but rather from experiential evidence. Kurman and Norris 5 observed no worsening of prognosis associated with fertility-sparing surgery in 182 patients who had tumors grossly confined to the ovary. Except in rare circumstances, fertility-sparing surgery with unilateral salpingo-oophorectomy has become the standard practice over the past two decades. For some patients, even ovarian cystectomy may be adequate surgical treatment of the involved ovary 17 ; however, this situation usually occurs before knowledge of the final diagnosis. Of course, the presence of dysgenetic gonads would definitely preclude such a strategy. The major purpose for fertility-sparing surgery-preservation of reproductive potential with subsequent pregnancy-is discussed below.
Comprehensive surgical staging. The principle of comprehensive surgical staging in apparent early-stage disease has been extrapolated from experience with epithelial ovarian cancer and has not been well studied in MOGCT. Nevertheless, most gynecologic oncologists subscribe to this principle and believe that comprehensive surgical staging most accurately determines the extent of disease, assists in determining prognosis, and potentially guides postoperative management. The key that leads to performance of surgical staging is intraoperative frozen-section examination of an ovarian mass in a young patient that confirms the diagnosis of a MOGCT. In the vast majority of cases in which surgical staging is not performed, the surgeon is a nongynecologic oncologist and/or no frozen-section examination is performed. Of course, an important adjunct to this entire process is the availability of an expert gynecologic pathologist who can diagnose a rare ovarian neoplasm.
Standard surgical staging in patients with apparent early-stage MOGCT consists of the following: peritoneal cytologic studies (washings or ascites); careful and systematic abdominal exploration, with inspection and palpation of all peritoneal surfaces; multiple biopsies of the pelvic and abdominal peritoneum, including posterior cul-de-sac, bladder reflection, bilateral pelvic sidewalls, bilateral paracolic spaces, and diaphragmatic surfaces; omentectomy; and retroperitoneal lymphadenectomy, including the bilateral pelvic and para-aortic lymph node areas.
Importantly, an intergroup study involving the Pediatric Oncology Group and the Children's Study Group found that deviations from standard surgical guidelines did not adversely affect survival. 18 Based on their findings, Billmire et al proposed new surgical guidelines: collection of ascites or cytologic washings, examination of the peritoneal surfaces with biopsy or excision of any nodules, examination and palpation of retroperitoneal lymph nodes and sampling of any firm or enlarged nodes, inspection and palpation of the omentum with removal if any adherent or abnormal areas are noted, biopsy of any abnormal areas, and complete resection of the tumor-containing ovary with sparing of the fallopian tube if not involved. Further study of this approach is clearly warranted.
Restaging of unstaged MOGCT. One of the clinical management dilemmas facing oncologists at the time of referral of a young patient with MOGCT who has not undergone comprehensive surgical staging is whether to recommend surgical restaging. Unfortunately, there is a paucity of information on this topic. Although minimally invasive surgical approaches are ideal for surgical restaging in such situations, the question arises as to whether surgical restaging will potentially contribute important information that will change subsequent management or improve prognosis. The information from the pediatric intergroup study would tend to speak strongly against the need for restaging, but, as stated, more study is needed. The general approach to such patients at our institution is to perform CT imaging, and if the ovarian mass has been satisfactorily managed and no abnormalities are noted on CT, to proceed with adjuvant chemotherapy. Exceptions could be a patient with unstaged dysgerminoma or grade 1 immature teratoma, for whom surveillance would be recommended for stage I disease, but observation is still a reasonable approach if imaging studies and tumor markers, such as hCG and AFP, are negative. If postoperative serum tumor markers are persistently elevated or initially decline and then plateau or rise, then it is likely that nondysgerminomatous elements or residual disease that requires adjuvant therapy may exist.
Cytoreductive surgery for advanced disease. The principle of primary cytoreductive surgery for patients with advanced-stage MOGCT has also been extrapolated from experience with epithelial ovarian cancer. Whether it is as important in the overall management of these very chemosensitive tumors, particularly dysgerminoma, remains unclear. However, there are reports that suggest a benefit from minimal residual disease at completion of primary surgical cytoreduction with both nonplatinum-and platinum-based chemotherapy regimens. 19, 20 In general, if one has a frozen-section diagnosis of an advanced-stage MOGCT, resection of all gross disease seems to be a very appropriate goal, tempered by safety/morbidity considerations in view of the excellent chemosensitivity of MOGCT.
Secondary Surgery
Second-look surgery. In general, second-look surgery is not recommended for patients with MOGCT. In a review of The University of Texas M.D. Anderson Cancer Center (Houston, TX) experience, second-look findings were negative in 52 of 53 patients. 21 One of the 52 negative patients subsequently relapsed and died. Thirteen patients had biopsy-proven evidence of mature teratoma-so-called chemotherapeutic retroconversion-at second-look surgery. Based on these findings, it was suggested that second-look surgery may be unnecessary in those patients with early-stage disease and positive serum tumor markers but might be considered in selected patients with advanced-stage disease or negative serum tumor markers. Subsequently, in a report of the Gynecologic Oncology Group, Williams et al 22 described 117 patients with MOGCT who underwent secondlook surgery after platinum-based chemotherapy. They concluded that patients with completely resected tumor or with advanced-stage incompletely resected tumor that does not contain elements of teratoma rarely, if ever, benefit from second-look surgery, but suggested that the procedure should be considered for patients with incompletely resected tumor that contains teratoma elements. However, included in this series were patients with clinically evident tumor before undergoing second-look surgery.
Secondary cytoreductive surgery. The value of secondary cytoreductive surgery for MOGCT remains unclear. There are, however, retrospective reports that suggest a possible role for secondary cytoreductive surgery in selected patients with recurrent MOGCT.
23,24
Munkarah et al 24 found that survival of patients with immature teratoma who underwent secondary surgery was superior to those with other histologic types. Ideal candidates for such consideration would be those with an isolated focus or limited foci of recurrent tumor.
POSTOPERATIVE THERAPY
Chemotherapy for Nondysgerminomatous Tumors
The evolution of the chemotherapeutic treatment of MOGCT constitutes the major advance in clinical management. Before the 1970s and the advent of combination chemotherapy, the prognosis for patients with MOGCT was rather dismal. Except for patients with dysgerminoma, virtually all patients with advanced-stage disease died, and, even in apparent stage I disease, only 5% to 20% of patients survived after surgery alone. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] In the 1970s, the combination of vincristine, dactinomycin, and cyclophosphamide became the standard. Although this regimen was moderately effective for patients with early-stage disease, the cure rate in patients with metastatic disease was less than 50%. 19, 25 With the introduction of platinum-based chemotherapy for testicular cancer, 26 the regimen of cisplatin, vinblastine, and bleomycin rapidly became the new standard for patients with MOGCT.
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Based on single-agent activity of etoposide in patients with refractory testicular cancer, a multi-institutional randomized trial found that, compared with the cisplatin, vinblastine, and bleomycin regimen, the combination of bleomycin, etoposide, and cisplatin (BEP) showed equal efficacy with less toxicity in patients with testicular cancer.
28 Subsequently, the BEP regimen became the new standard for patients with MOGCT 29,30 and remains so to the present. Experience to date indicates that the cure rates for patients with early-stage MOGCT approach 100%, and even in advanced-stage disease, cure rates are at least 75%. Major unresolved issues include the optimal number of cycles, particularly for patients with advanced-stage disease, and the selection of those patients who can safely undergo surveillance (see later).
Chemotherapy for Dysgerminoma
Dysgerminoma has always stood apart from the other cell types with the MOGCT classification based on its exquisite radiosensitivity. Thus, even before the modern combination chemotherapy era, radiotherapy was the traditional postoperative treatment for patients with metastatic dysgerminoma with excellent outcomes. However, although ovarian shielding was used in some centers, subsequent infertility secondary to ovarian failure was the norm for young patients. In the 1980s, particularly with the introduction of the platinum-based regimens, chemotherapy essentially replaced radiotherapy as standard treatment for patients with metastatic dysgerminoma, with fertility preservation in most patients.
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Trend Toward Surveillance
Historically, the only patients thought to be appropriate candidates for treatment with surgery alone were those with stage IA dysgerminoma and stage IA, grade 1 immature teratoma. However, there is a strong trend toward exploring the feasibility of surgery followed by close surveillance in a much broader group of patients, although further study is warranted. Bonazzi et al 35 reported the findings of a prospective trial in which 22 patients with stage I or II, grade 1 or 2, immature teratoma of the ovary were treated with surgery alone. Of these, 12 were followed clinically with abdominopelvic sonography at regular intervals, and 10 underwent at least one second-look surgery. The peritoneal findings of two patients with gliomatosis peritonei remained unchanged during the 2 years following surgery. Two patients-stage IA, grade 2 and stage IC, grade 2-had bulky abdominal recurrences with grade 0 tumor. Both were salvaged with repeat surgery.
Dark et al 36 enrolled 24 patients with stage IA MOGCT into a surveillance program postoperatively. Excluding the nine patients with dysgerminoma, nine had immature teratoma, and six had yolk sac tumor. Three of these 15 (20%) patients relapsed. The two patients with yolk sac tumor each relapsed at 4 months, and both were salvaged with combination chemotherapy. The third patient became pregnant before second-look surgery; she presented with ascites and hepatic metastases during the third trimester, 13 months after diagnosis, and died of pulmonary embolus 4 weeks into chemotherapy. Mitchell et al 37 reported nine patients with stage I MOGCT-six with immature teratoma, four of which were grade 2 tumors, and three with mixed germ cell tumor, all with yolk sac tumor elements. At the time of the report, with follow-up times of 12 to 182 months, only one patient had relapsed; she had immature teratoma of unknown grade and recurred 8 months after a unilateral salpingo-oophorectomy.
Two further reports from the Pediatric Oncology Group/Children's Cancer Group Intergroup also expand on the experience with the strategy of surgery alone. 38 ,39 Cushing et al 38 described 44 patients with completely resected ovarian immature teratoma, grades 1 to 3 (31 pure and 13 with yolk sac tumor elements). Ten of 12 patients evaluated for serum AFP had elevated levels. The 4-year event-free and overall survival for the two groups was 97.7% and 100%, respectively. One patient with a mixed tumor relapsed 18 weeks after primary surgery with a rising AFP level. She was treated with four cycles of BEP and was alive disease-free 57 months after completing chemotherapy. Two other studies-one from Germany and the other from Francereported a total of 39 girls with stage I MOGCT who were treated with surgery plus observation. 40, 41 The overall survival for the combined studies was 97.4%; 13 patients relapsed, and 12 were salvaged with chemotherapy.
Based on the foundation of the previous pediatric studies, the Children's Oncology Group is currently studying the approach of surgery plus surveillance in patients with stage I MOGCT. Although this strategy appears to be very promising, further study, particularly in adult patients, will be required to assure its safety and efficacy.
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LATE EFFECTS OF THERAPY
There is a fairly robust literature on reproductive function after chemotherapy for MOGCT, albeit exclusively retrospective. 33, [42] [43] [44] [45] However, there is very little information on psychological, physical, and sexual function postchemotherapy in this group of patients. In a questionnaire study of 40 patients with MOGCT who were treated with fertility-sparing surgery plus chemotherapy, mostly nonplatinum-based regimens, 33 patients (83%) were having menstrual function, and one patient reported premature menopause. 42 Of the 16 patients who attempted pregnancy, 11 delivered 22 healthy infants. Four subsequent reports have documented that at least 80% of patients with MOGCT who were treated with fertility-sparing surgery and platinum-based chemotherapy had normal menstrual function, and there are several documented normal pregnancies 33,43-45 (Table 2) . However, it is well known that a proportion of women may experience premature menopause following chemotherapy. 46 A recently completed Gynecologic Oncology Group prospective questionnaire study of survivors of MOGCT and controls focusing on physical, sexual, psychosocial, and reproductive functioning is currently being analyzed.
A second major area of concern with regard to late effects of chemotherapy for patients with MOGCT is secondary malignancy related to etoposide. 47, 48 The development of acute myelogenous leukemia appears to be related to cumulative dose.
TREATMENT OF RECURRENT MOGCT
Most patients with MOGCT are cured, but a small percentage does develop recurrence. Most recurrences occur within 24 months of primary diagnosis. 23 Because of the rarity of relapse in this population, there is no standard approach, with treatment strategies extrapolated from clinical experience with testicular cancer patients. In testicular cancer, the most commonly employed salvage regimens include vinblastine, ifosfamide, and cisplatin; etoposide, ifosfamide, and cisplatin; or paclitaxel, ifosfamide, and cisplatin. [49] [50] [51] [52] For patients with persistent, refractory, or platinum-resistant (relapse within 6 weeks of completing platinum-based chemotherapy) recurrent tumor, the prognosis is much worse, and high-dose chemotherapy with stem-cell rescue appears to be favored. [53] [54] [55] However, the salvage rate in patients with MOGCT appears to be no better than 50%. Furthermore, a recent randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy plus stem-cell rescue as first-line therapy for patients with poor-prognosis metastatic germ cell tumors did not demonstrate any improvement in outcome for patients who received high-dose chemotherapy with stem-cell rescue.
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SUMMARY
In summary, patients with MOGCT have an excellent prognosis, with cure rates approaching 100% for those with early-stage disease and at least 75% for patients with advanced-stage disease. Fertility-sparing surgery is feasible in most patients, and at least 80% of these who receive postoperative chemotherapy will retain reproductive function. The role of comprehensive surgical staging or restaging for unstaged patients remains unclear. Although BEP chemotherapy is the standard for most patients, there is a growing trend toward surveillance; however, further study of this approach is warranted. For those few patients who relapse, up to 50% may be salvaged with further treatment.
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